Melanie R. Rupert

Let me verify her tracked cases and prior firm history through more reliable sources.

Let me verify the notable case outcomes and her prior firm history through legal-industry sources.

Melanie R. Rupert — Patent Litigation Summary

Focus areas. Rupert's practice is concentrated in life sciences patent litigation, principally Hatch-Waxman/ANDA disputes and related validity challenges over small-molecule drug products. Her tracked matters involve antiemetic/CINV drug patents (Helsinn's Akynzeo/Aloxi franchise, in both the Gland Pharma and Azurity matters), and her published case record covers oncology, CNS and medical-device technologies. There is no indication of Wi-Fi/standards, software, or mechanical patent work in her tracked appearances or practice descriptions; Paul Hastings lists her as a partner in the firm's Life Sciences IP practice in New York, focused on pharmaceutical, biotechnology and medical-device litigation.

Side preference. She works for innovator/branded pharmaceutical companies — i.e., patent owners and operating companies — rather than for NPEs/PAEs. The tracked list (1 plaintiff-side, 3 defendant-side appearances) is consistent with that: she was trial counsel for Helsinn as plaintiff in Helsinn Healthcare S.A. v. Gland Pharma Ltd., and back-up counsel for Helsinn, this time as the defendant/patent owner, in the Azurity Pharmaceuticals v. Helsinn Healthcare litigation (which also generated the parallel PTAB proceedings). Both roles are the same client-side posture — enforcing and defending a branded drug franchise — not an NPE enforcement model.

Firm context. Rupert is a partner in the Litigation Department at Paul Hastings LLP in New York, where firm materials describe her as a leader in the Life Sciences IP group. Court records place her as Paul Hastings (then Paul Hastings Janofsky & Walker) counsel in the Galderma/Supernus litigation as early as 2011, so her tenure at the firm spans well over a decade. Earlier firm affiliations are not reliably documented in the legal-press or firm sources reviewed, so I would not state prior employers; third-party people-search listings that reference other firms are not a source I would rely on.

Notable matters. Verifiable highlights include the Delaware jury verdict for AbbVie/Allergan against Revance establishing infringement of three Botox®-related patents and awarding $56 million on a 27% reasonable royalty (the firm's team was led by Eric Dittmann, with Rupert among the partners). She was also counsel in Allergan v. MSN Laboratories, where the Federal Circuit recognized the "first-filed, first-issued" exception to obviousness-type double patenting — cited as protecting Allergan's Viberzi® patents and named a 2025 "Impact Case of the Year" by Managing IP and LMG Life Sciences. Other reported results include a defense win for Eisai and Merck in a New Jersey Hatch-Waxman case over lenvatinib (Lenvima®), and an Eisai win against Shilpa Medicare upholding purity-patent claims after a bench trial. Her tracked Helsinn v. Gland Pharma matter resolved by consent judgment and dismissal in December 2022, under which Gland admitted technical infringement of the Helsinn patents via its ANDA.

PTAB experience. She appears regularly in PTAB proceedings as back-up counsel rather than lead. She was back-up counsel for patent owner Helsinn in the Azurity v. Helsinn IPRs (IPR2025-00945 through -00949, challenging the '826, '357, '515, '297 and related patents; instituted in part in November 2025), and her pro hac vice admission as back-up counsel was granted in January 2026. She was also co-lead counsel for Eisai in a post-grant review (PGR2021-00047) that ended in a Federal Circuit Rule 36 affirmance of a PTAB holding invalidating a third-party polymorph patent. She is admitted pro hac vice before the Board rather than as a registered practitioner.

Bar / education. Admitted to the New York bar (2002); J.D., NYU School of Law (2001); B.S., Cornell University, biological sciences with a molecular and cell biology concentration (1998).